Sanofi SA Deal History & Licensing Activity
Sanofi SA is a life sciences. Over the past three years, Sanofi SA has been involved in 20 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (10 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
11
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Autoimmune
Sanofi SA Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sanofi SA in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| MRT5400 / MRT5401 | Sanofi | mRNA | Phase 2 | collaboration | Apr 2026 |
| AXPAXLI | Sanofi | Other | Phase 3 | acquisition | Mar 2026 |
| KT501 | Sanofi | Bispecific Antibodies | Phase 1 | license | Mar 2026 |
Sanofi SA Pipeline Focus
Therapeutic areas and modalities where Sanofi SA is most active based on deal history and clinical trial data.
Therapeutic Areas
Sanofi SA Strategic Signals
Key indicators of Sanofi SA's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Sanofi SA Clinical Pipeline
Sanofi SA has 50 active clinical trials across 6 development phases.
14
Unknown
4
Phase 4
3
Not Applicable
5
Phase 1
9
Phase 2
15
Phase 3
See How Your Asset Matches Sanofi SA's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Sanofi SA Licensing & Deal Activity
Sanofi SA is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 20 deals over the past three years, Sanofi SA ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi SA include Autoimmune (16 deals and trials), Immunology (11 deals and trials), Infectious Disease (7 deals and trials), and Metabolic (6 deals and trials). In terms of modality, Sanofi SA has shown particular interest in bispecific antibodies, other, mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi SA and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sanofi SA's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.